SIPAI HEALTH (00314) plans to sell 100% equity of Supremo Technology (Guangzhou) for a total of RMB 51.73 million.

SIPAI HEALTH (00314) announced that on April 22, 2026, SPI Investment (a wholly-owned subsidiary of the company) (as the seller) entered into a share transfer agreement with DaShenLin Pharmaceutical Group (as the buyer). According to the agreement, SPI Investment conditionally agreed to sell all of its equity in its target company, SIPAI Zhihe Technology (Guangzhou) Co., Ltd., for a total consideration of RMB 51.73 million. As part of the sale, the company will also transfer its equity in its two subsidiary companies, Weite and Beijing Renbo, to the target company, which will also be part of the target group being sold by the company. After the completion of the sale, the group will no longer hold any equity in the target company, and the target company will no longer be a subsidiary of the group, and its assets and liabilities will no longer be included in the group's consolidated financial statements. DaShenLin Pharmaceutical Group will acquire 100% equity in the target subsidiary company and target company. The company will periodically review the group's assets strategically to enhance shareholder value. Since 2024, the group has prioritized commercial health insurance and health management services as key development areas. With strong industry trends and policy support, these business segments have shown strong growth momentum, with significantly higher gross profit margins than the specialty pharmacy business. Considering the current market conditions in the pharmacy industry and the operating performance of the target company and its subsidiary pharmacy business, the board believes that the sale will allow the group to further focus on its core strategy, optimize resource allocation, strengthen financial support for its core business, improve the overall gross profit margin of the group, and accelerate the achievement of the group's overall profit target.